Atrium Therapeutics (RNA)
Targets genetic drivers of rare cardiomyopathies with tissue-directed siRNA medicines.
Something off on this page? Send us feedback.
Develops targeted, non-viral siRNA medicines for rare genetic cardiomyopathies. Its narrow pipeline includes ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy.
Develops targeted, non-viral siRNA medicines for rare genetic cardiomyopathies. ATR 1072 targets PRKAG2 syndrome, while ATR 1086 targets PLN cardiomyopathy; additional targets remain at the research stage.
Built around a delivery platform that pairs tissue-selective antibodies or other delivery ligands with oligonucleotides, the pipeline seeks to reach heart tissue and address genetic drivers rather than symptoms. The company was separated from Avidity and began Nasdaq trading in 2026.
Near-term execution depends on the planned clinical study of ATR 1072, progress toward an IND for ATR 1086, and continued development of cardiac-tissue delivery.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 6, 2026 | H.C. Wainwright | Initiate | Rating: —Target: — | Target: $25 |
| Jun 18, 2026 | Cantor Fitzgerald | Target | Target: — | Target: $25 |
| May 15, 2026 | Leerink Partners | Target | Target: — | Target: $25 |
| Oct 29, 2025 | TD Cowen | Downgrade | ||
| Oct 28, 2025 | RBC Capital | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $264.2M · Total debt $1.7M · Total assets $280.5M · Shareholders' equity $214.6M
- Revenue
- $3.0M
- Operating income
- −$22.6M
- Net income
- −$20.2M
No dividends on record.
| Institutions | 84.59% | 14.47M shares | |
|---|---|---|---|
| 159 holders · as of Jun 30, 2026 | |||
| Insiders | 2.87% | 491.7K shares | |
| 8 holders · as of Sep 22, 2026 | |||
| Other | 12.54% | 2.14M shares | |
| remainder | |||
17.11M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Sessa Capital Im, L.P.Institution | 8.77% | 1.50M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 8.61% | 1.47M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.46% | 1.45M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.27% | 730,831 | as of Jun 30, 2026 |
CRCM LPInstitution | 3.75% | 641,539 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Tenaya Therapeutics
Gene therapies targeting inherited cardiomyopathies
- Lexeo Therapeutics
AAV gene therapies for genetic cardiomyopathies
- Alnylam Pharmaceuticals
Approved RNAi medicine for ATTR cardiomyopathy
- Rocket Pharmaceuticals
AAV therapies across inherited cardiomyopathy subtypes
- BridgeBio Pharma
Approved medicine for transthyretin amyloid cardiomyopathy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Atrium Therapeutics | $8.57 | −7.10% | $157.7M | — | — | 6.7 | — |
| Tenaya Therapeutics | $0.6693 | −1.89% | $148.0M | — | — | 110.9 | — |
| Lexeo Therapeutics | $3.55 | −12.83% | $319.6M | — | — | — | — |
| Alnylam Pharmaceuticals | $247.38 | −1.70% | $33.67B | 42.5 | 29.4 | 7.0 | +66.9% |
| Rocket Pharmaceuticals | $3.15 | −6.01% | $365.8M | — | — | — | — |
| BridgeBio Pharma | $66.08 | −4.55% | $13.56B | — | — | 19.6 | +120.4% |
| Median | 42.5 | 29.4 | 19.6 | +93.6% |